New treatment gains special designation for rare gastric cancer cases
- HCB101 gets FDA orphan drug designation
- Treatment aimed at gastric cancer
- Special status for rare disease therapies
Hanchorbio has secured FDA orphan drug designation for its investigational treatment HCB101, aimed at addressing gastric cancer. This designation is granted to encourage the development of treatments for rare diseases, highlighting the need for innovative solutions in oncology. The FDA’s recognition underscores the potential impact of HCB101 for patients suffering from this condition.
The orphan drug designation allows Hanchorbio to benefit from various incentives, including market exclusivity upon approval, protocol assistance, and tax credits for clinical trial costs. Gastric cancer, often diagnosed in advanced stages, has limited treatment options, making HCB101 an important focus for ongoing research and development. This move reflects the company’s commitment to improving outcomes for those impacted by rare cancer types.
With this designation, Hanchorbio can expedite the development of HCB101, enhancing the hope for better treatment options in gastric cancer therapy. The designation is part of a broader strategy to address unmet medical needs within oncology, where effective therapies are urgently required.
